ing obstructive uropathy including reports of pelvic extramedullary erythropoiesis among the non-thalassaemic disorders.7-9

The cortical irregularity and coarsening of the trabecular pattern of the lumbosacral spines as shown in the CT scan suggested that the extramedullary erythropoiesis in our patient represented extrusion of proliferating marrow through the cortex rather than embolization of circulating totipotential cells as was proposed by Ask-Upmark.9 In the previous study of the CT features of presacral extramedullary erythropoiesis masses in thalassaemias, irregularity and erosion of the anterior cortex of the sacrum were also observed.4,6

In order to decompress the erythropoietic mass, radiation is often the treatment of choice10 since the mass is highly radiosensitive and surgical interven-

tion may result in massive haemorrhage due to the high vasculature of the tumour.11 Issaragrisil et al. reported a prompt response of the mass with spinal cord compression to deep X-ray therapy at a dose of 2,000–3,000 rad.12 The erythropoietic mass in our patient however did not respond satisfactorily to radiation. The relatively huge mass and hypoxic autoinfarction, as demonstrated by Tc-99m sulphur colloid marrow image, could be responsible for this radiotolerant effect,13 and early surgical decompression should be considered in such cases.

Acknowledgement

The authors wish to thank Professor Henry Wilde for his review of the manuscript. Dr Ti is a recipient of China Medical Board Scholar Development Fund No. 85-441.

References

4. Chao, P.W., Farman, J. & Kapelner, S. CT features of presacral mass: an unusual focus of extramedullary hemato-

6. Geminis, T., Philippou, A., Gouliamos, A. et al. Atypical location of extramedullary erythropoietic masses in thalas-

9. Ask-Upmark, E. Tumor stimulating intrathoracic hetero-

10. Sorsdahl, O.S., Taylor, P.E. & Noyes, W.D. Extramedullary hemato-

12. Issaragrisil, S., Piankijagum, A. & Wasi, P. Spinal cord compression in thalassemia. Report of 12 cases and recom-


Malignant phaeochromocytoma and hypercalcaemia

J.A. Bridgewater, W.A. Ratcliffe1, N.J. Bundred2 and C.W.I. Owens

Department of Clinical Pharmacology, Rayne Institute, University College Hospital, London WC1E 2JJ, and 1Wolfson Research Laboratories and 2University Department of Surgery, Queen Elizabeth Hospital, Birmingham B15 2TH, UK

Summary: We describe a case of hypercalcaemia secondary to recurrent malignant phaeochromocytoma. Parathyroid-related protein (PTHrp 1–86) immunoreactivity was identified in plasma and PTHrp was identified by immunocytochemistry in tumour tissue.

Correspondence: J.A. Bridgewater
Accepted: 23 July 1992
Introduction

The association of phaeochromocytoma with hypercalcaemia is infrequent but well documented, and usually (although not always) occurs with multiple endocrine adenomatosis type II. Hypercalcaemia in this context has been attributed to either stimulation of bone resorption, excessive parathyroid hormone (PTH) production secondary to catecholamines or increased production of PTH or a PTH-like humoral agent by the tumour. In 1987, a hypercalcaemic factor with potent PTH-like bioactivity, structurally homologous with PTH at its NH2-terminus was isolated from tumours and cancer cell lines. This factor, called PTH-related protein (PTHrp) is now thought to be an important humoral mediator of hypercalcaemia in patients with solid tumours. Thus mRNA for PTHrp has been identified in tumours associated with humoral hypercalcaemia of malignancy and PTHrp has been localized in tumour tissue by immunohistochemistry. Recently plasma levels of PTHrp have been shown to be increased in a high proportion of patients with cancer-associated hypercalcaemia.

The recent demonstration of PTHrp mRNA and PTHrp immunoreactivity in a benign phaeochromocytoma prompted us to report our own case of hypercalcaemia secondary to PTHrp in recurrent malignant phaeochromocytoma.

Case report

A 68 year old retired taxi driver was first noted to have hypertension in 1978, easily controlled with a modest dose of metoprolol and chlorthalidone. Routine measurement of catecholamines prior to entry into a clinical trial revealed noradrenaline concentrations of 17.1 nmol/l supine and 18.1 nmol/l standing (reference range 0.5–3.5 nmol/l supine). Urinary vanillymmandelic acid (VMA) was 80 µmol/24 hours (reference range 9–36). Computed tomographic (CT) scan confirmed the presence of a 7 cm left phaeochromocytoma. Surgical excision of the tumour occurred without incident and serum catecholamines returned to normal. Subsequently he was treated with a combination of enalapril and bendrofluazide which kept pressures in the range of 140/80 mmHg, pulse 72 supine, 118/80 mmHg, pulse 92 standing.

Eight years following resection of his original tumour, he presented with symptoms of intermittent constipation, malaise and worsening memory. He was found to be anaemic (haemoglobin 8.0 g/dl normocytic and normochromic), hypercalcaemic (calcium 3.24 mmol/l, albumin 36 g/l) and to have an erythrocyte sedimentation rate (ESR) of 128 mm/hour. An abdominal ultrasound and CT scan located a left para-aortic mass thought likely to be recurrent phaeochromocytoma.

The hypercalcaemia was treated with a single intravenous infusion of pamidronate (15 mg) with some improvement in his mental state but investigations including parathyroid ultrasound, technetium bone scan, serum parathyroid hormone <1.5 pmol/l (reference range 1–5), serum 1, 25-OH vitamin D 15 ng/ml (reference range 3–30), calcitomin 0.08 µg/ml (reference range <0.08) and myeloma screen were negative. Plasma PTHrp 1–86, measured by a sensitive two-site immuno metric assay, was raised (0.7 pmol/l (reference range <0.25)). One month following treatment with pamidronate, the serum calcium began to rise again (calcium 2.82 mmol/l, albumin 36 g/l) but not to levels requiring further treatment.

Although the para-aortic mass was felt most likely to be a recurrent phaeochromocytoma, it was difficult to prove it. The patient was normotensive off antihypertensive treatment, urinary VMA values were only borderline, the MIBG scan was normal and a CT-guided needle biopsy of the para-aortic mass did not yield a histological diagnosis. Laparotomy, however, revealed malignant para-aortic lymphadenopathy, the histology of which was phaeochromocytoma, very similar to histology obtained 8 years earlier. Immunohistochemical staining of the laparotomy tumour tissue specimen using a rabbit antiserum to PTHrp 37–69 was positive.

Only immediately preoperatively (and post-operatively), did he become hypertensive requiring intravenous labetalol. Plasma noradrenaline (12.6 pmol/ml (0.5–3.5)) and urinary VMA (70 µmol/24 hours (9–36)) was elevated but plasma adrenaline remained normal – characteristic of a non-adrenal source of catecholamine. Blood pressure returned to normal without treatment 5 days later. He subsequently died of bronchopneumonia one month following laparotomy.

Discussion

This case illustrates several interesting aspects of phaeochromocytoma. Long-term recurrence is well described up to 30 years but continues to surprise. Recurrence as a malignant tumour is less common and has a less favourable prognosis. Episodic hypertension is described as commonly as 50% and in our patient was only present immediately pre- and post-operatively. This hypertension was easily controlled with relatively small doses of labetalol. Presentation with hypercalcaemia is uncommon but well described, although only in non-malignant cases. Serum and tissue identification of PTHrp makes it likely that PTHrp was the cause of hypercalcaemia in this patient.
References